Head-to-head evidence
albuterol / budesonide vs Beclomethasone (QVAR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
Beclomethasone (QVAR)
Marketed by Teva Pharmaceutical Industries
NCT00109668 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with over 400 patients, which gives it solid design fundamentals. However, no results have been posted, and the record does not state what the primary outcome measure actually was, so the strength of the eventual evidence cannot yet be confirmed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · Beclomethasone (QVAR)'s landscape